Dishman Carbogen Amcis Ltd
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]
- Market Cap ₹ 1,921 Cr.
- Current Price ₹ 122
- High / Low ₹ 148 / 80.0
- Stock P/E
- Book Value ₹ 371
- Dividend Yield 0.00 %
- ROCE 1.03 %
- ROE -0.14 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.33 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.32% over past five years.
- Company has a low return on equity of -0.76% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -3.85%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | |
1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | |
Operating Profit | 452 | 445 | 552 | 503 | 274 | 331 | 332 |
OPM % | 26% | 26% | 27% | 25% | 14% | 15% | 14% |
26 | 46 | 54 | 39 | 16 | 29 | -20 | |
Interest | 49 | 49 | 57 | 62 | 48 | 57 | 86 |
Depreciation | 214 | 211 | 240 | 283 | 308 | 308 | 281 |
Profit before tax | 216 | 231 | 309 | 197 | -65 | -4 | -55 |
Tax % | 33% | 33% | 32% | 20% | -154% | 524% | 45% |
Net Profit | 145 | 155 | 210 | 159 | -165 | 18 | -30 |
EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | |
Dividend Payout % | 0% | 0% | 2% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | 6% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -117% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -15% |
3 Years: | 19% |
1 Year: | 3% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 1% |
3 Years: | -1% |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
0 | 32 | 32 | 31 | 31 | 31 | 31 | |
Reserves | 4,814 | 5,075 | 5,347 | 5,684 | 5,667 | 5,518 | 5,778 |
950 | 1,095 | 1,042 | 1,357 | 1,589 | 1,830 | 2,209 | |
811 | 967 | 899 | 1,121 | 1,068 | 1,255 | 1,435 | |
Total Liabilities | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,454 |
4,852 | 5,066 | 5,098 | 5,678 | 5,698 | 5,773 | 6,235 | |
CWIP | 133 | 151 | 175 | 234 | 486 | 780 | 996 |
Investments | 40 | 196 | 167 | 191 | 172 | 324 | 249 |
1,550 | 1,757 | 1,881 | 2,091 | 2,000 | 1,758 | 1,973 | |
Total Assets | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,454 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
303 | 226 | 282 | 585 | 513 | 355 | 220 | |
-107 | -297 | -169 | -442 | -380 | -619 | -448 | |
-137 | 78 | -102 | -98 | -11 | 130 | 250 | |
Net Cash Flow | 59 | 7 | 11 | 46 | 122 | -133 | 22 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
Debtor Days | 61 | 96 | 79 | 103 | 80 | 81 | 89 |
Inventory Days | 473 | 525 | 496 | 462 | 402 | 526 | 574 |
Days Payable | 95 | 201 | 176 | 226 | 132 | 158 | 157 |
Cash Conversion Cycle | 439 | 419 | 399 | 340 | 350 | 449 | 506 |
Working Capital Days | 117 | 129 | 135 | 124 | 135 | 115 | 116 |
ROCE % | 5% | 6% | 4% | 0% | 1% | 1% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report for the year ended March 31, 2023, issued by Mr. Ashok P. Pathak & Co., Practicing Company Secretaries.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
29 May - Listing Obligations and Disclosures Requirements) Regulations, 2015, pls. find enclosed herewith transcript of earnings conference call arranged by the Company with Investors on Tuesday, 23rd …
- DISCLOSURES OF RELATED PARTY TRANSACTIONS PURSUANT TO REGULATION 23 (9) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURES REQUIREMENTS) REGULATIONS, 2015 23 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
23 May - Listing Obligations and Disclosures Requirements) Regulations, 2015, the audio recording of Conference Call arranged by the Company with Investors on Tuesday, 23rd May, 2023 which …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
23 May - Listing Obligations and Disclosures Requirements) Regulations, 2015, pls. find enclosed herewith Presentation on financial result for the quarter and year ended 31st March, 2023 to …
Annual reports
Concalls
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Sep 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
Business Segments
CRAMS Vertical (~77% of total revenues)[1]
The company is an integrated Contract Research & Manufacturing Services (CRAMS) player with strong capabilities across the value chain. It assists drug innovators in development and optimization of processes for novel drug molecules in various stages of the development process. [2]
Presently, the company has a total of 27 commercialized molecules and 17 molecules in phase-3 (last stage) of manufacturing optimization. During the year 3 new molecules were commercialized. [3]
It earns ~83% of CRAMS revenues from Switzerland, France & China. [4]